Structure
Clear review logic
Insurance cases benefit from a clean sequence of findings, evidence, clinical relevance and benefit-related assessment.
Insurance-related reports
Reports for insurers
Human genetics assessments for benefits reviews, risk-related evaluations and complex causation questions, focused on plausibility, functional impact and prognosis.
Benefits review
Assessment of genetic diagnoses in relation to functional impairment, expected course and insurance relevance.
Disability / invalidity
Evaluation of whether and to what extent a genetic disorder affects actual capacity and performance.
Causation and differentiation
Clear distinction between genetic findings, manifested symptoms and competing explanations.
Supplemental specialist opinions
Focused reassessment of individual findings, variants or course-related questions within ongoing reviews.
What insurers need
No over-interpretation of genetic findings
For insurers, the decisive question is whether a genetic finding is actually functionally and benefit-relevant in the individual case. The assessment therefore separates molecular evidence, clinical manifestation, prognosis and insurance relevance strictly.
| Review aspect | Expert focus |
|---|---|
| Diagnostic certainty | Whether the genetic diagnosis is sufficiently secured and clinically plausible. |
| Functional impact | Which objectively supportable limitations actually follow from the condition. |
| Prognosis | Expected course based on natural history and available evidence. |
| Limits of the opinion | Where the data allow a robust conclusion and where they do not. |
Plausibility
Genotype is not automatically benefit-relevant
Especially in rare variants and heterogeneous syndromes, the decisive issue is the actual clinical expression in the person under review.
Efficiency
Defined document checklist
Medical records, genetic findings, the exact review question and a deadline are usually sufficient for a robust first assessment of feasibility.
Typical insurance-related scenarios
Typical cases include genetic syndromes, hereditary cancer predisposition, neuromuscular disorders, skeletal disorders, developmental disorders or unclear variants with claimed functional relevance. In all such settings, the diagnosis alone is insufficient; what matters is whether there is a sufficiently robust link to functional loss, prognosis or the insured event.
A common error is the assumption that a molecular diagnosis automatically proves a defined level of impairment. A robust report instead evaluates which manifestations are actually present, how consistent the course is and whether competing or additional factors need to be taken into account.
The result is a precise assessment that is directly usable for insurers and clearly distinguishes established conclusions, plausible assumptions and remaining limits.
Helpful for rapid pre-review
Useful are the review question, contract or case context, relevant medical reports, genetic findings, available course information and the desired turnaround window.
Independence
Independent, evidence-based and free of party influence
All expert reports are prepared independently, without influence from involved parties, and based solely on the medical file, the documented genetic findings and current scientific standards.